Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness
By analyzing two large and diverse datasets from multiple perspectives, we obtained reliable results that the trastuzumab originator and its biosimilars have similar safety profiles. The concurrent use of pertuzumab was also found to be safe. The use of biosimilars can lead to cost savings. These findings provide crucial insights for the evaluation and adoption of biosimilars in clinical practice.
Authors
- Shinichi Toyooka (ORCID: https://orcid.org/0000-0002-7588-6745)
- Takahiro Tsukioki
- Maki Tanioka (ORCID: https://orcid.org/0000-0002-6558-2246)
- Hirofumi Hamano (ORCID: https://orcid.org/0000-0002-2231-0179)
- Kenji Takada (ORCID: https://orcid.org/0000-0001-9306-6639)
- Tsuguo Iwatani (ORCID: https://orcid.org/0000-0001-7162-1515)
- Tadahiko Shien (ORCID: https://orcid.org/0000-0003-3202-5512)
- T. Mamori
- Yuko Takahashi
Institutions
- Okayama University (JP)
- Okayama University Hospital (JP)
Publication Details
- Journal
- BioDrugs
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1007/s40259-024-00686-x
- Citations
- 3
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Celltrion
- Okayama University